Authors: Helena M. Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Adrian Harnett, Mei-Lin Ah-See, Richard Simcock, Daniel Rea, Sanjay Raj, Pamela Woodings, Mark Harries, Donna L. Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Janine Mansi, Ioannis Gounaris, Betania Mahler Araujo, Elena Provenzano, Anita Chhabra, Jean Abraham, Carlos Caldas, Peter Hall, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David Cameron, Janet A. Dunn, Roshan Agarwal, Hafiz Algurafi, Rozenn Allerton, Caroline Archer, Anne C Armstrong, Catherine Bale, Lisa H Barraclough, Urmila Barthakur, Carolyn Bedi, Kim Benstead, D. Bloomfield, Rebecca Bowen, Chris Bradley, Jane Brown, Mohammad Butt, Mark Churn, Susan Cleator, Joanne Cliff, Perric Crellin, Margaret Daly, Shiroma De Silva-Minor, A.S. Dhadda, O.S. Din, Sue Down, H. M. Earl, David J. Eaton, Andrew Eichholz, Daniel Epurescu, Chee Goh, Andrew D. Goodman, Robert Grieve, Maher Hadaki, Catherine Harper-Wynne, Larry Hayward, A. Humphreys, Helen Innes, Mariam Jafri, Apurna Jegannathen, Muireann Kelleher, Hartmut Kristeleit, Daniela Lee, Susan Lupton, Carol MacGregor, Zafar Malik, Jennifer Marshall, Trevor McGolick, Rakesh Mehra, Natasha Mithal, Charlotte Moss, Aian Moss, Mukesh Mukesh, Anthony Neal, Daniel Nelmes, Helen Neville-Webbe, Jacqueline Newby, S O'Reilly, Peter Ostler, Mojca Persic, Laura Pettit, Fharat A. Raja, Catherine Reed, Anne Rigg, Helen Roe, Nihal Shah, Peter Simmonds, Eliot Sims, Sarah Smith, Nicola Storey, Wendy Taylor, Narottam Thanvi, Karen Tipples, Jayant S. Vaidya, Mohini Varughese, Anup Vinayan, Nawaz Walji, Simon Waters, Kathryn Wright, Sundus Yahya

Venue: The Lancet

Type: Publication

Abstract: Background: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival.Methods: This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly ... (read more)

DOI: 10.1016/s0140-6736(19)30650-6